MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|Journal of Clinical Oncology|2017Cited by 1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|JAMA Oncology|2019Cited by 983
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyW. Eiermann, Semiglazov Vf, Stefan Paepke et al.|Annals of Oncology|2001Cited by 714
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination TrialMitch Dowsett, Aman U. Buzdar, Hironobu Sasano et al.|Journal of Clinical Oncology|2008Cited by 464
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline TreatmentKathy S. Albain, Joyce O’Shaughnessy, Shona Nag et al.|Journal of Clinical Oncology|2008Cited by 422